The expression levels and prognostic value of high temperature required A2 (HtrA2) in NSCLC

Pathology Research and Practice

Volumn 210, Issue 12, 2014, Pages 939-943

  Mao, Guoxin ^a   Lv, Liting ^a   Liu, Yifei ^a   Chen, Buyou ^a   Li, Mei ^a   Ni, Tingting ^a   Yang, Dunpeng ^a   Zhu, Hongzhen ^a   Xue, Qun ^a   Ni, Runzhou ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Apoptosis; HtrA2; Non small cell lung cancer; Prognosis

Indexed keywords

CASPASE; CISPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN SERINE KINASE; RNA; SERINE PROTEINASE OMI; MITOCHONDRIAL PROTEIN; SERINE PROTEINASE;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSOL; FEMALE; FLOW CYTOMETRY; GENE DELETION; HIGH TEMPERATURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; PROGNOSIS; RNA INTERFERENCE; SERINE ENDOPEPTIDASES;

EID: 84949114464     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2014.06.030     Document Type: Article

References (29)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60(5):277-300.
2. Ji X.D., Li G., Feng Y.X., Zhao J.S., Li J.J., Sun Z.J., et al. EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 2011, 71(3):1156-1166.
3. Rachidi S.M., Qin T., Sun S., Zheng W.J., Li Z. Molecular profiling of multiple human cancers defines an inflammatory cancer-associated molecular pattern and uncovers KPNA2 as a uniform poor prognostic cancer marker. PLoS One 2013, 8(3):e57911.
4. Biswas G., Guha M., Avadhani N.G. Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene 2005, 354:132-139.
5. Mathiasen I.S., Jaattela M. Triggering caspase-independent cell death to combat cancer. Trends Mol. Med. 2002, 8(5):212-220.
6. Reed J.C. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 2001, 7(7):314-319.
7. Fabregat I., Roncero C., Fernandez M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int. 2007, 27(2):155-162.
8. Al Dhaheri Y., Eid A., AbuQamar S., Attoub S., Khasawneh M., Aiche G., et al. Mitotic arrest and apoptosis in breast cancer cells induced by Origanum majorana extract: upregulation of TNF-alpha and downregulation of survivin and mutant p53. PLoS One 2013, 8(2):e56649.
9. Kargi H.A., Aktas S., Sagol O., Ermete S., Akpinar O., Akkoclu A. Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC). Cancer Lett. 1997, 116(2):185-189.
10. Lademann U., Cain K., Gyrd-Hansen M., Brown D., Peters D., Jaattela M. Diarylurea compounds inhibit caspase activation by preventing the formation of the active 700-kilodalton apoptosome complex. Mol. Cell. Biol. 2003, 23(21):7829-7837.
11. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407(6805):770-776.
12. van Loo G., Saelens X., van Gurp M., MacFarlane M., Martin S.J., Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002, 9(10):1031-1042.
13. Okada M., Adachi S., Imai T., Watanabe K., Toyokuni S.Y., Ueno M., et al. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004, 103(6):2299-2307.
14. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7(7):646-657.
15. Kooistra J., Milojevic J., Melacini G., Ortega J. A new function of human HtrA2 as an amyloid-beta oligomerization inhibitor. J. Alzheimers Dis. 2009, 17(2):281-294.
16. Martins L.M., Morrison A., Klupsch K., Fedele V., Moisoi N., Teismann P., et al. Neuroprotective role of the reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell. Biol. 2004, 24(22):9848-9862.
17. Zurawa-Janicka D., Jarzab M., Polit A., Skorko-Glonek J., Lesner A., Gitlin A., et al. Temperature-induced changes of HtrA2(Omi) protease activity and structure. Cell Stress Chaperones 2013, 18(1):35-51.
18. Tain L.S., Chowdhury R.B., Tao R.N., Plun-Favreau H., Moisoi N., Martins L.M., et al. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ. 2009, 16(8):1118-1125.
19. Luo F., Wei L., Sun C., Chen X., Wang T., Li Y., et al. HtrA2/Omi is involved in 6-OHDA-induced endoplasmic reticulum stress in SH-SY5Y cells. J. Mol. Neurosci. 2012, 47(1):120-127.
20. Hu X.Y., Xu Y.M., Chen X.C., Ping H., Chen Z.H., Zeng F.Q. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. APMIS 2006, 114(12):893-898.
21. Wang C.Y., Lin Y.S., Su W.C., Chen C.L., Lin C.F. Glycogen synthase kinase-3 and Omi/HtrA2 induce annexin A2 cleavage followed by cell cycle inhibition and apoptosis. Mol. Biol. Cell 2009, 20(19):4153-4161.
22. Cilenti L., Soundarapandian M.M., Kyriazis G.A., Stratico V., Singh S., Gupta S., et al. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J. Biol. Chem. 2004, 279(48):50295-50301.
23. Hu X., Chen X., Ping H., Chen Z., Zeng F., Lu G. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2005, 25(6):671-673.
24. Ouyang Y.Q., zur Hausen A., Orlowska-Volk M., Jager M., Bettendorf H., Hirschfeld M., et al. Expression levels of hnRNP G and hTra2-beta1 correlate with opposite outcomes in endometrial cancer biology. Int. J. Cancer 2011, 128(9):2010-2019.
25. Barr M.P., Gray S.G., Hoffmann A.C., Hilger R.A., Thomale J., O'Flaherty J.D., et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 2013, 8(1):e54193.
26. Zhang Y.X., Yue Z., Wang P.Y., Li Y.J., Xin J.X., Pang M., et al. Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth. Biomed. Pharmacother. 2013, 67(2):97-102.
27. Cetintas V.B., Kucukaslan A.S., Kosova B., Tetik A., Selvi N., Cok G., et al. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol. Int. 2012, 36(3):261-265.
28. Narkiewicz J., Lapinska-Szumczyk S., Zurawa-Janicka D., Skorko-Glonek J., Emerich J., Lipinska B. Expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes in primary endometrial cancer. Oncol. Rep. 2009, 21(6):1529-1537.
29. Kaminskyy V.O., Piskunova T., Zborovskaya I.B., Tchevkina E.M., Zhivotovsky B. Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy 2012, 8(7):1032-1044.